Gene · 1806
Papers4,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
861 to 880 of 4,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. | Front Pharmacol | 2022 | 35662713 | PubTator, text mining | PubMed |
| A Novel lncRNA Panel for Risk Stratification and Immune Landscape in Breast Cancer Patients. | Int J Gen Med | 2022 | 35655656 | PubTator, text mining | PubMed |
| Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database. | Ther Adv Drug Saf | 2022 | 35646307 | PubTator, text mining | PubMed |
| The Emerging Role of Long Non-Coding RNAs in Esophageal Cancer: Functions in Tumorigenesis and Clinical Implications. | Front Pharmacol | 2022 | 35645836 | PubTator, text mining | PubMed |
| Confounding factors in the assessment of oral mucositis in head and neck cancer. | Support Care Cancer | 2022 | 35639187 | PubTator, text mining | PubMed |
| The Dihydrouridine landscape from tRNA to mRNA: a perspective on synthesis, structural impact and function. | RNA Biol | 2022 | 35638108 | PubTator, text mining | PubMed |
| A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes. | Pharmaceuticals (Basel) | 2022 | 35631462 | PubTator, text mining | PubMed |
| Technical Performance of a 430-Gene Preventative Genomics Assay to Identify Multiple Variant Types Associated with Adult-Onset Monogenic Conditions, Susceptibility Loci, and Pharmacogenetic Insights. | J Pers Med | 2022 | 35629091 | PubTator, text mining | PubMed |
| Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application. | Int J Environ Res Public Health | 2022 | 35627569 | PubTator, text mining | PubMed |
| Biomarkers of Favorable vs. Unfavorable Responses in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy. | Cells | 2022 | 35626648 | PubTator, text mining | PubMed |
| Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. | Diagnostics (Basel) | 2022 | 35626213 | PubTator, text mining | PubMed |
| Multiscale Characterization of Type I Collagen Fibril Stress-Strain Behavior under Tensile Load: Analytical vs. MD Approaches. | Bioengineering (Basel) | 2022 | 35621471 | PubTator, text mining | PubMed |
| A Case Report and Review of the Literature of Penile Metastasis From Rectal Cancer. | Front Surg | 2022 | 35615651 | PubTator, text mining | PubMed |
Predictive Biomarkers for Antipsychotic Treatment Response in Early Phase of Schizophrenia: Multi-Omic Measures Linking Subcortical Covariant Network, Transcriptomic Signatures, and Peripheral Epigenetics. | Front Neurosci | 2022 | 35615285 | PubTator, text mining | PubMed |
| Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping. | Clin Pharmacol Ther | 2022 | 35607723 | PubTator, text mining | PubMed |
| Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial. | Sci Rep | 2022 | 35595817 | PubTator, text mining | PubMed |
| Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine. | Sci Rep | 2022 | 35595780 | PubTator, text mining | PubMed |
| Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation. | Evid Based Complement Alternat Med | 2022 | 35591866 | PubTator, text mining | PubMed |
| Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). | Trials | 2022 | 35590388 | PubTator, text mining | PubMed |
| Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors. | J Oncol | 2022 | 35586209 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1806/papers?page=44